Evidence map›Paper›PMID 26521258›Full record

Trial reportEuropean journal of clinical pharmacology2016

A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS).

David Ternant, Gilles Paintaud, Howard Trachtman, Debbie S Gipson, Melanie S Joy

Abstract readClinical Trial, Phase ILetterRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Interventions for focal segmental glomerulosclerosis in adults.The Cochrane database of systematic reviews · 2022
    Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

David TernantCNRS, GICC UMR 7292, CHRU de Tours, Service de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, 2 boulevard Tonnellé, 37044, Tours Cedex, France. david.ternant@univ-tours.fr.
Gilles PaintaudCNRS, GICC UMR 7292, CHRU de Tours, Service de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, 2 boulevard Tonnellé, 37044, Tours Cedex, France.
Howard TrachtmanDivision of Nephrology, NYU Langone Medical Center, New York, NY, USA.
Debbie S GipsonSchool of Medicine, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
Melanie S JoySkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.
Centre Hospitalier Universitaire de Tours · FRNYU Langone Health · USUniversité de Tours · FRUniversity of Colorado Anschutz Medical Campus · USUniversity of Michigan–Ann Arbor · US

Funding

Novel Therapies for Resistant FSGSR33DK070341 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI TRACHTMAN, HOWARD · 2008 to 2011
$1.5M
Novel Therapies for Resistant FSGSR21DK070341 · NIDDK · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI TRACHTMAN, HOWARD · 2005 to 2006
$435k
NIDDK NIH HHS R21 DK070341NIDDK NIH HHS R33 DK070341
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdalimumabAdolescentAdultAge FactorsChildFemaleGlomerulosclerosis, Focal SegmentalHumansInjections, SubcutaneousMaleModels, BiologicalSubcutaneous AbsorptionYoung AdultAdalimumab

Identifiers

PMID26521258
OpenAlexW1901118290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.